Progress of research on diabetes with hypertension aggravating vascular disease

Abstract

Abstract: The major cause of morbidity and mortality of diabetes is cardiovascular disease, which is exacerbated by hypertension. Diabetes and hypertension are closely interlinked because of similar risk factors, and there is also substantial overlap in the cardiovascular complications of diabetes and hypertension. Controlling comorbidities, especially hypertension, is important in reducing the vascular complications of diabetes.

Key words: diabetes, hypertension, comorbidities, cardiovascular complications

CLC Number:

LIU Ning, ZHANG Wei-hua. Progress of research on diabetes with hypertension aggravating vascular disease[J]. Basic & Clinical Medicine, 2020, 40(7): 990-994.

References

[1] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843. doi: 10.1016/j.diabres.2019.107843.
[2] Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries[J]. Circulation, 2016, 134: 441-450.
[3] Horr S, Nissen S. Managing hypertension in type 2 diabetes mellitus[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30: 445-454.
[4] Choby B. Diabetes update: prevention and management of diabetes complications[J]. FP Essent, 2017, 456: 36-40.
[5] Fishman SL, Sonmez H, Basman C, et al. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review[J]. Mol Med, 2018, 24: 59-90.
[6] Luc K, Schramm-Luc A, Guzik TJ, et al. Oxidative stress and inflammatory markers in prediabetes and diabetes[J]. J Physiol Pharmacol, 2019, 70. doi: 10.26402/jpp.2019.6.01.
[7] Zhang Y, Sun X, Icli B, et al. Emerging roles for microRNAs in diabetic microvascular disease: Novel targets for therapy[J]. Endocr Rev, 2017, 38: 145-168.
[8] Antoniades C. ‘Dysfunctional' adipose tissue in cardiovascular disease: A reprogrammable target or an innocent bystander?[J]. Cardiovasc Res, 2017, 113: 997-998.
[9] Camastra S, Vitali A, Anselmino M, et al. Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery[J]. Sci Rep, 2017, 7: 9007-9025.
[10] Jung UJ. Choi MS. Obesity and its metabolic complica-tions: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease[J]. Int J Mol Sci, 2014, 15: 6184-6223.
[11] Shi X, Wang S, Luan H, et al. Clinopodium chinense attenuates palmitic acid-induced vascular endothelial inflammation and insulin resistance through TLR4-mediated NF-kappa B and MAPK pathways[J]. Am J Chin Med, 2019, 47: 97-117.
[12] Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension[J]. Hypertension, 2017, 70: 660-667.
[13] Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both?[J]. Curr Diab Rep, 2014, 14: 453-471.
[14] Nigro C, Leone A, Raciti GA, et al. Methylglyoxal-glyoxalase 1 balance: the root of vascular damage[J]. Int J Mol Sci, 2017, 18: E188.doi:10.3390/ijms18010188.
[15] Manigrasso MB, Juranek J, Ramasamy R, et al. Unlock-ing the biology of RAGE in diabetic microvascular complications[J]. Trends Endocrinol Metab, 2014, 25: 15-22.
[16] Koulis C, Watson AM, Gray SP, et al. Linking RAGE and Nox in diabetic micro- and macrovascular complications[J]. Diabetes Metab, 2015, 41: 272-281.
[17] Correction to: 2016 ATVB plenary lecture: receptor for advanced glycation endproducts and implications for the pathogenesis and treatment of cardiometabolic disorders: Spotlight on the macrophage[J]. Arterioscler Thromb Vasc Biol, 2017, 37: e66.doi:10.1161/ATV.0000000000000057.
[18] Meza CA, La Favor JD, Kim DH, et al. Endothelial dysfunction: Is there a hyperglycemia-induced imbalance of NOX and NOS?[J]. Int J Mol Sci, 2019, 20: 3775.doi:10.3390/ijms20153775.
[19] Petrie JR, Guzik TJ, and Touyz RM. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms[J]. Can J Cardiol, 2018, 34: 575-584.
[20] Guzik TJ, Cosentino F. Epigenetics and immunometabolism in diabetes and aging[J]. Antioxid Redox Signal, 2018, 29: 257-274.
[21] Naidoo V, Naidoo M, Ghai M. Cell- and tissue-specific epigenetic changes associated with chronic inflammation in insulin resistance and type 2 diabetes mellitus[J]. Scand J Immunol, 2018, 88: e12723. doi: 10.1111/sji.12723.
[22] Hyun MH, Lee Y, Choi BG, et al. Roles of achieved levels of low-density lipoprotein cholesterol and high-sensitivity c-reactive protein on cardiovascular outcome in statin therapy[J]. Cardiovasc Ther, 2019, 2019: 1-11.
[23] Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy[J]. Cardiovasc Res, 2017, 113: 389-398.
[24] Banerjee J, Nema V, Dhas Y, et al. Role of microRNAs in type 2 diabetes and associated vascular complications[J]. Biochimie, 2017, 139: 9-19.
[25] Sharma A, Rizky L, Stefanovic N, et al. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction[J]. Cardiovasc Diabetol, 2017, 16: 33-56.